188
Participants
Start Date
March 6, 2023
Primary Completion Date
November 22, 2029
Study Completion Date
November 22, 2029
Osimertinib 80 mg/40 mg
Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
Research Site, Hualien City
Research Site, Manila
Research Site, Quezon City
Research Site, Cebu
Research Site, Taipei
Research Site, White Plains
Research Site, Bangkok
Research Site, Seongnam-si
Research Site, Gyeonggi-do
Research Site, Granada
Research Site, Milan
Research Site, Incheon
Research Site, Sondrio
Research Site, Kuantan
Research Site, Brescia
Research Site, Madrid
Research Site, Cheongju-si
Research Site, Udine
Research Site, Daejeon
Research Site, Peschiera del Garda
Research Site, Taichung
Research Site, Seville
Research Site, Reggio Emilia
Research Site, Valencia
Research Site, Bilbao
Research Site, Busan
Research Site, Busan
Research Site, Kuala Lumpur
Research Site, Lecce
Research Site, Napoli
Research Site, Kaohsiung City
Research Site, Avellino
Research Site, Las Vegas
Research Site, Songkhla
Research Site, Palermo
Research Site, Kuching
Research Site, Santa Rosa
Research Site, Singapore
Research Site, Hong Kong
Research Site, Kaohsiung City
Research Site, Hong Kong
Research Site, Hong Kong
Research Site, Terni
Research Site, Goyang-si
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Badalona
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, London
Research Site, Nottingham
Lead Sponsor
AstraZeneca
INDUSTRY